SCHEMBL4500469

SCHEMBL4500469

CN(C(=O)C(C)(C)N)c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccccc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPC1 O15118 3/20 0.35
POLB P06746 1/20 0.35
AHR P35869 1/20 0.35
KDR P35968 6/20 0.34
FLT4 P35916 2/20 0.34
FLT3 P36888 2/20 0.34
TGM2 P21980 1/20 0.34
KIT P10721 1/20 0.34
CES1 P23141 1/20 0.33
BACE1 P56817 1/20 0.33
NPY2R P49146 1/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL227304 0.95 KDR (0.36) LRRK2NPC1POLBAHRKDR
SCHEMBL4506120 0.92 LRRK2 (0.42) LRRK2RXFP1NPC1POLBAHR
SCHEMBL5856822 0.91 BACE1 (0.36) LRRK2NPC1POLBAHRKDR
SCHEMBL4485052 0.91 RXFP1 (0.36) LRRK2RXFP1NPC1KDRTGM2
SCHEMBL4502977 0.91 NPC1 (0.37) LRRK2NPC1POLBAHRKDR
SCHEMBL4490904 0.90 CCNB2 (0.35) LRRK2POLBFLT4FLT3TGM2
SCHEMBL4485965 0.90 NR1H4 (0.39) MAPT
SCHEMBL4503993 0.90 NPC1 (0.34) LRRK2RXFP1NPC1POLBAHR
SCHEMBL4481482 0.90 SENP1 (0.35) RXFP1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4493874 0.90 CASP3 (0.35) LRRK2RXFP1POLBKDRFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR LRRK2 168/4885RXFP1 425/4885NPC1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.